Effectiveness and safety of Sofosbuvir/Velpatasvir for chronic hepatitis C in Buriram hospital, Thailand

Abstract

Background: In Thailand, chronic hepatitis C can now be effectively cured with Direct Acting agents(DAAs) which have demonstrated high treatment efficacy. Certain DAA regimens can treat multiple genotypes without requiring prior genotype testing.
Objective: To evaluate the treatment outcomes and adverse effects of the Sofosbuvir/Velpatasvir regimen in patients with chronic hepatitis C, comparing those who received Ribavirin with those who did not, at Buriram Hospital.
Methods: This study is a retrospective study involving 150 patients with chronic hepatitis C who received treatment with the Sofosbuvir/Velpatasvir regimen. Data were analyzed from blood test results and hepatitis C viral load before and after treatment. Additionally, factors influencing treatment outcomes were assessed, and adverse drug reactions were evaluated.
Results: The study included 150 patients, comprising 103 males and 47 females. The results showed a significant reduction in AST levels in the group receiving Ribavirin compared to the non-treated group (p=0.015). The APRI score (the ratio of AST to platelet count) also decreased more significantly in the treated group than in the untreated group (p=0.001). The sustained virologic response (SVR) rate in this study was as high as 95.3%. Reported adverse effects included anemia in 3.3% of patients and drug-induced hepatitis in 6.0% of patients. Notably, no cases of drug allergy or severe complications, such as chest pain or drug-induced rash, were observed.
Conclusion: Treatment of chronic hepatitis C with DAAs is highly effective, achieving an SVR rate of 95.3%. The most common adverse effects observed were mild anemia and non-severe hepatitis.